NEW YORK, July 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Joseph Slattery has been appointed to the Exosome Diagnostics Board of Directors.
Mr. Slattery, 48, brings significant finance and diagnostic industry experience to the Company. He currently serves as Chief Financial Officer and Executive Vice President of Baxano Surgical, Inc. (formerly TranS1 Inc.), a medical device company focused on minimally invasive lumbar fusion technology. Mr. Slattery also serves as a Director and Chairman of the Audit Committee of CVRx, Inc., a medical device company developing proprietary active implantable technology for the treatment of high blood pressure and hypertension. Prior to joining Baxano Surgical, Mr. Slattery was Chief Financial Officer and Senior Vice President of Digene Corporation, a molecular diagnostics company focused on women's health and infectious disease. During his eleven-year tenure at Digene, the company went public, grew annual revenues from $5 million to over $200 million, established its DNA test for Human Papillomavirus as a critical component of cervical cancer screening in the United States, and expanded its operations internationally. Digene was acquired by QIAGEN, N.V. in 2007 for $1.6 billion. Mr. Slattery received a B.S. degree in Accountancy from Bentley University and is a Certified Public Accountant.
"Joe brings strong diagnostic industry and capital markets experience to Exosome Diagnostics," said James McCullough, Chief Executive Officer of Exosome Diagnostics. "We are delighted he is joining our board as we expand our commercial efforts in the life sciences and clinical diagnostics markets."
Mr. Slattery stated, "Exosome Diagnostic's opportunity as a disruptive platform technology in molecular diagnostics is substantial. I am very excited to work with James and the rest of the Board to help the Company realize its potential."
About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are packaged and shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome diagnostic technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic products for use in companion diagnostic applications, detection, and real-time monitoring of disease. The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.
SOURCE Exosome Diagnostics